Inhibitors of multidrug resistance to antitumor agents (MDR).
about
Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problemSmall and Innovative Molecules as New Strategy to Revert MDRSynthesis and biochemical characterization of new phenothiazines and related drugs as MDR reversal agents.Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis.Mechanism targeted discovery of antitumor marine natural products.P-Glycoprotein/MDR1 regulates pokemon gene transcription through p53 expression in human breast cancer cellsFluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.The relevance of higher plants in lead compound discovery programs.Strategies for reversing drug resistance.Clinical relevance of P-glycoprotein in drug therapy.Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team upPotential role of drug transporters in the pathogenesis of medically intractable epilepsy.Impact of fungal drug transporters on fungicide sensitivity, multidrug resistance and virulence.Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications.Discovery of novel antitumor antimitotic agents that also reverse tumor resistance.Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug Resistance.Silencing of ETS1 reverses adriamycin resistance in MCF-7/ADR cells via downregulation of MDR1.Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity.The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells.Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.1-Cyclohexyl-4-(4-arylcyclohexyl)piperazines: Mixed σ and human Δ(8)-Δ(7) sterol isomerase ligands with antiproliferative and P-glycoprotein inhibitory activity.ABCB1 Structural Models, Molecular Docking, and Synthesis of New Oxadiazolothiazin-3-one Inhibitors.Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors.Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells.Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells.Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization.Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins.Concise and very efficient synthesis of the N-methylwelwistatin tetracyclic core based on an anionic domino process.Convergent evolution of medicines.How many traditional Chinese medicine components have been recognized by modern Western medicine? A chemoinformatic analysis and implications for finding multicomponent drugs.Design, synthesis, and biological evaluation of 6-methoxy-2-arylquinolines as potential P-glycoprotein inhibitors.Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?miRNAs for the Detection of MultiDrug Resistance: Overview and PerspectivesPharmacological Profile of Quinoxalinone
P2860
Q26829549-920367CC-5AD2-4678-AC90-E668C2880114Q27012455-007E20C8-FF94-4D5A-86CD-5C0066B535BDQ30319387-55953055-D7D0-465B-8DA9-F092D9B8323FQ30877068-61D48670-C86D-48EF-A2BA-5FA5C5A0AD9FQ34012630-1BDDC20B-389B-4439-B92E-DDE588B9DFBEQ34205543-D5407F01-82F9-4245-8A1C-BB83393DEC3CQ34613849-9526E24F-C48E-4D17-A875-64539576B507Q35172533-331A3736-C46A-4BCA-81B8-347C6A723771Q35567287-61391AB3-A6BC-4B00-98CD-64DEF2E22C56Q35620664-A7606233-CAE9-4421-B9F1-0E75DC8C7223Q35720625-60033C3B-3CCA-4E26-B4A3-BEE1606746CBQ36023613-9A40BB07-D398-42F9-96FA-B4A71C32988AQ36395321-CD7186C2-0AE3-495B-AF14-4459D5A8183CQ36555922-44974AB3-2ECC-40C6-B9F4-67E96C9967ADQ37380736-72B0D6E2-B90E-4D5A-8C8A-526FBA5BC79AQ38748106-D844C94D-CB99-4A91-9BDB-AC316EB5001AQ38901160-A24E7EDB-60E4-4B17-8FF2-3D826D5FA637Q39084283-A2EB3FE3-1F2D-44CC-B036-0CF3C69DD790Q39470004-CB6640C9-6021-412A-A3E5-A0559038FFCAQ39547723-F3837EE9-5494-4DA0-B64D-E2C63F9FB4FCQ39633191-B2BD0F15-64C9-4990-8C54-E5650AED8B35Q39780798-48DC2D2C-E76A-49F6-B660-2340CFC2976BQ39895966-D62B3A27-399D-450F-8B01-3F01F9FDFEB9Q40239521-D03CC6C0-B39A-491E-A2EA-8695B660DD5AQ40582811-4299D643-8308-4808-80A6-AC752D89E40EQ40604578-900C7861-9A3C-436E-AF6A-96546AF4D48BQ42585002-11FBD026-5DC5-4FAF-A6B5-4C9EB3C77AA6Q42934492-9AD25222-E6E1-4A08-B46E-04FEFD859170Q47685388-8909D7BA-6DFC-41B1-AA7D-BD523770739AQ47737161-FAD5D04C-A578-4354-B723-6618820F2C31Q49677744-032A8A94-4B46-401A-8B23-DCADBE0C7949Q53841527-5F421AF7-6378-4F80-A79F-B46B0F3901C7Q58798114-6D1FF24D-BB04-4450-8EBA-70F21C35708DQ58988424-298F42EA-08CC-4428-B333-E97D3DFCF366Q59054635-8C949A95-059C-458F-A980-33DA5F02D0C8
P2860
Inhibitors of multidrug resistance to antitumor agents (MDR).
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Inhibitors of multidrug resistance to antitumor agents (MDR).
@ast
Inhibitors of multidrug resistance to antitumor agents (MDR).
@en
Inhibitors of multidrug resistance to antitumor agents
@nl
type
label
Inhibitors of multidrug resistance to antitumor agents (MDR).
@ast
Inhibitors of multidrug resistance to antitumor agents (MDR).
@en
Inhibitors of multidrug resistance to antitumor agents
@nl
prefLabel
Inhibitors of multidrug resistance to antitumor agents (MDR).
@ast
Inhibitors of multidrug resistance to antitumor agents (MDR).
@en
Inhibitors of multidrug resistance to antitumor agents
@nl
P356
P1476
Inhibitors of multidrug resistance to antitumor agents (MDR).
@en
P2093
Carmen Avendaño
J Carlos Menéndez
P304
P356
10.2174/0929867023371175
P577
2002-01-01T00:00:00Z